Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have received an average recommendation of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month target price […]
Commodore Capital LP boosted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 610,000 shares of the biotechnology company’s stock after buying an additional 35,000 shares during the period. Arrowhead Pharmaceuticals accounts […]
Commodore Capital LP grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.1% during the second quarter, Holdings Channel.com reports. The fund owned 610,000 shares of the biotechnology company’s stock after purchasing an additional 35,000 shares during the quarter. Arrowhead Pharmaceuticals makes up 2.4% of Commodore Capital LP’s investment portfolio, making the […]
Research analysts at Bank of America began coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) in a research report issued on Monday, Briefing.com reports. The firm set a “buy” rating and a $29.00 price target on the biotechnology company’s stock. Bank of America‘s target price suggests a potential upside of 25.16% from […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its price target dropped by Morgan Stanley from $40.00 to $37.00 in a report released on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s target price would indicate a potential upside of 43.91% from the stock’s previous […]